Stock Track | Monopar Therapeutics Soars 8.74% on Bullish Analyst Rating and $130 Price Target

Stock Track11-19

Shares of Monopar Therapeutics (MNPR) surged 8.74% during intraday trading on Tuesday, following a bullish report from JonesTrading analyst Soumit Roy. The analyst maintained a "Buy" rating on the stock and set an impressive price target of $130.00, signaling strong confidence in the company's future prospects.

Roy's optimistic outlook appears to be driven by promising data from Monopar's ALXN1840 drug candidate and the company's robust financial position. While specific details of the ALXN1840 data were not disclosed, the positive sentiment suggests potential advancements in Monopar's drug development pipeline, which could significantly impact the company's growth trajectory.

The substantial price target of $130.00 implies considerable upside potential for Monopar Therapeutics' stock, attracting investor attention and likely contributing to today's sharp price increase. As the biotech sector continues to garner interest from both institutional and retail investors, Monopar's strong analyst backing and promising drug candidates position the company as an attractive investment opportunity in the evolving healthcare landscape.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1132483281?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-19 03:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1132483281","market":"sg","top_or_hot":-1,"title":"Stock Track | Monopar Therapeutics Soars 8.74% on Bullish Analyst Rating and $130 Price Target","media":"Stock Track","content":"<p>Shares of Monopar Therapeutics (MNPR) surged 8.74% during intraday trading on Tuesday, following a bullish report from JonesTrading analyst Soumit Roy. The analyst maintained a \"Buy\" rating on the stock and set an impressive price target of $130.00, signaling strong confidence in the company's future prospects.</p>\n\n<p>Roy's optimistic outlook appears to be driven by promising data from Monopar's ALXN1840 drug candidate and the company's robust financial position. While specific details of the ALXN1840 data were not disclosed, the positive sentiment suggests potential advancements in Monopar's drug development pipeline, which could significantly impact the company's growth trajectory.</p>\n\n<p>The substantial price target of $130.00 implies considerable upside potential for Monopar Therapeutics' stock, attracting investor attention and likely contributing to today's sharp price increase. As the biotech sector continues to garner interest from both institutional and retail investors, Monopar's strong analyst backing and promising drug candidates position the company as an attractive investment opportunity in the evolving healthcare landscape.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Monopar Therapeutics Soars 8.74% on Bullish Analyst Rating and $130 Price Target</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Monopar Therapeutics Soars 8.74% on Bullish Analyst Rating and $130 Price Target\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-11-19 03:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Monopar Therapeutics (MNPR) surged 8.74% during intraday trading on Tuesday, following a bullish report from JonesTrading analyst Soumit Roy. The analyst maintained a \"Buy\" rating on the stock and set an impressive price target of $130.00, signaling strong confidence in the company's future prospects.</p>\n\n<p>Roy's optimistic outlook appears to be driven by promising data from Monopar's ALXN1840 drug candidate and the company's robust financial position. While specific details of the ALXN1840 data were not disclosed, the positive sentiment suggests potential advancements in Monopar's drug development pipeline, which could significantly impact the company's growth trajectory.</p>\n\n<p>The substantial price target of $130.00 implies considerable upside potential for Monopar Therapeutics' stock, attracting investor attention and likely contributing to today's sharp price increase. As the biotech sector continues to garner interest from both institutional and retail investors, Monopar's strong analyst backing and promising drug candidates position the company as an attractive investment opportunity in the evolving healthcare landscape.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MNPR","symbol_name":"Monopar Therapeutics","start_time":0,"source_url":"","article_id":"1132483281","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1132483281","pubTimestamp":1763492541,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Monopar Therapeutics (MNPR) surged 8.74% during intraday trading on Tuesday, following a bullish report from JonesTrading analyst Soumit Roy. The analyst maintained a \"Buy\" rating on the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MNPR":"Monopar Therapeutics"},"translate_title":"股票追踪|Monopar Therapeutics飙升8.74%，分析师评级看涨，目标价130美元","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MNPR":1},"content_text":"Shares of Monopar Therapeutics (MNPR) surged 8.74% during intraday trading on Tuesday, following a bullish report from JonesTrading analyst Soumit Roy. The analyst maintained a \"Buy\" rating on the stock and set an impressive price target of $130.00, signaling strong confidence in the company's future prospects.\nRoy's optimistic outlook appears to be driven by promising data from Monopar's ALXN1840 drug candidate and the company's robust financial position. While specific details of the ALXN1840 data were not disclosed, the positive sentiment suggests potential advancements in Monopar's drug development pipeline, which could significantly impact the company's growth trajectory.\nThe substantial price target of $130.00 implies considerable upside potential for Monopar Therapeutics' stock, attracting investor attention and likely contributing to today's sharp price increase. As the biotech sector continues to garner interest from both institutional and retail investors, Monopar's strong analyst backing and promising drug candidates position the company as an attractive investment opportunity in the evolving healthcare landscape.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1132483281","isCrawlerRequest":true}